Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
Journal: Frontiers in oncology
Published: April 02, 2025
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Journal: Nature medicine
Published: August 07, 2024
Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Journal: Breast cancer research and treatment
Published: May 11, 2023
Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time.
Journal: Research square
Published: April 17, 2023
Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.
Journal: Cardio-oncology (London, England)
Published: March 31, 2023
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
Journal: Breast cancer research and treatment
Published: September 26, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Journal: NPJ breast cancer
Published: September 12, 2021
The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer.
Journal: Breast cancer research and treatment
Published: August 12, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Journal: Cancer cell
Published: December 07, 2020
Last Updated: 09/26/2026